ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

domvanalimab

Also written as “Domvanalimab” and “Domvanalimab (DOM)”.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Adenocarcinoma Of Esophagus · Squamous Cell Carcinoma of Head and Neck, led by 3 companies.

Drug pageDomvanalimab: every studyAll 19 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 12, 202210 company-led studies, 6 open or runningNext primary completion: Mar 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciencesits history only55 open or runningphase 3since Aug 12, 2022Apr 26, 2018Mar 2027phase 2 · NCT06727565
Arcus Biosciences40 open or runningphase 3since Oct 3, 2022Jul 26, 2018none ahead
AstraZenecaits history only11 open or runningphase 3since Jan 11, 2022Jan 11, 2022none ahead

Also a collaborator on its studies: Otsuka and Merck KGaA, Darmstadt, Germany.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Arcus Biosciences only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Jul 26, 2018First study: phase 1 study in Solid Tumor, Unspecified, AdultFirst studyNCT03628677 · 75 enrolled · United States, Australia
  2. Dec 19, 2020Named domvanalimabINNProposed as its International Nonproprietary Name in WHO's List 124
  3. Jan 29, 2021Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04736173 · 169 enrolled · United States, Hong Kong, Malaysia and more
  4. Apr 8, 2022Phase 2 study in Adenocarcinoma Of EsophagusNCT05329766 · 332 enrolled · United States, Canada, Chile and more
  5. Oct 3, 2022Phase 3 study in Adenocarcinoma Of EsophagusNCT05568095 · 1,040 enrolled · United States, Argentina, Australia and more

TargetBeta

TIGIT →read by rule
“A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the co-inhibitory molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT), ”NCIt, by rule
“T-cell immunoreceptor with Ig and ITIM domains inhibitor”ChEMBL 37, by rule

Other programs on TIGIT

ProgramCompanyFurthest phaseStudies
rilvegostomigAstraZenecaphase 324
nilvanstomigruleSuzhou Zelgen Biopharmaceuticalsphase 315
BC008-1Arulesichuan-luzhou-buchang-biopharmaceutical-co-ltdphase 12

Studies

All 4 Arcus Biosciences leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05568095Adenocarcinoma Of Esophagus · United States, Argentina, Australia and more3CompletedAug 28, 20261,040
NCT05329766Adenocarcinoma Of Esophagus · United States, Canada, Chile and more2CompletedSep 7, 2026332
NCT04736173Carcinoma, Non-Small-Cell Lung · United States, Hong Kong, Malaysia and more2CompletedSep 17, 2026169
NCT03628677Solid Tumor, Unspecified, Adult · United States, Australia1CompletedJan 23, 202575

How it is read

Names in the registry

  • “Domvanalimab”, 9 entries
  • “Domvanalimab (DOM)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.